Edition:
United States

ZIOPHARM Oncology Inc (ZIOP.OQ)

ZIOP.OQ on NASDAQ Stock Exchange Capital Market

4.57USD
17 Nov 2017
Change (% chg)

$-0.17 (-3.59%)
Prev Close
$4.74
Open
$4.83
Day's High
$4.83
Day's Low
$4.41
Volume
546,154
Avg. Vol
270,773
52-wk High
$7.88
52-wk Low
$4.04

Latest Key Developments (Source: Significant Developments)

Ziopharm Oncology reports third quarter financial results
Monday, 6 Nov 2017 04:05pm EST 

Nov 6 (Reuters) - Ziopharm Oncology Inc :Ziopharm Oncology reports third quarter 2017 financial results and provides update on recent activities.Q3 loss per share $0.13.Q3 earnings per share view $-0.14 -- Thomson Reuters I/B/E/S.  Full Article

Ziopharm Oncology reports Q2 loss per share $0.13
Monday, 31 Jul 2017 04:05pm EDT 

July 31 (Reuters) - Ziopharm Oncology Inc :Ziopharm Oncology reports second quarter 2017 financial results and provides update on recent activities.Q2 loss per share $0.13.Q2 earnings per share view $-0.13 -- Thomson Reuters I/B/E/S.Qtrly collaboration revenue $1.6 million versus $1.7 million.  Full Article

CVI Investments reports 6.8 pct passive stake in Ziopharm Oncology
Monday, 22 May 2017 04:21pm EDT 

May 22 (Reuters) - Ziopharm Oncology Inc ::CVI Investments Inc reports a 6.8 percent passive stake in Ziopharm Oncology Inc as of May 11, 2017 - sec filing.  Full Article

ZIOPHARM Oncology says offering of 9.71 mln common shares priced at $5.15/shr
Friday, 12 May 2017 09:20am EDT 

May 12 (Reuters) - Ziopharm Oncology Inc :Ziopharm oncology announces pricing of $50 million follow-on offering of common stock.Says offering of 9.71 million common shares priced at $5.15per share.Says offering of 9.71 million common shares priced at $5.15per share.  Full Article

ZIOPHARM announces FDA acceptance of IND for CD33-specific CAR-T cell therapy
Tuesday, 2 May 2017 07:00am EDT 

May 2 (Reuters) - ZIOPHARM Oncology Inc :Ziopharm oncology announces fda acceptance of ind for cd33-specific car-t cell therapy targeting relapsed/refractory acute myeloid leukemia.Ziopharm oncology inc - investigator-initiated ind application to fda for a phase 1 trial infusing cd33-specific car(+) t therapy is now active.Ziopharm oncology inc - first patient to be enrolled in study expected to begin treatment in q3 of 2017..  Full Article

Ziopharm Oncology reports Q1 loss per share $0.15
Monday, 1 May 2017 04:05pm EDT 

May 1 (Reuters) - Ziopharm Oncology Inc :Ziopharm Oncology reports first quarter 2017 financial results and provides update on recent activities.Q1 loss per share $0.15.Q1 earnings per share view $-0.12 -- Thomson Reuters I/B/E/S.Ziopharm -ended quarter with cash and cash equivalents of about $66.4 million, which it believes will be sufficient to fund currently planned activities through Q4.  Full Article

Ziopharm Q4 loss per share $0.11
Thursday, 16 Feb 2017 04:05pm EST 

Ziopharm Oncology Inc : Ziopharm reports fourth-quarter 2016 financial results and provides update on recent activities . Q4 loss per share $0.11 .Q4 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S.  Full Article

Ziopharm Q2 loss per share $1.01
Tuesday, 9 Aug 2016 04:01pm EDT 

Ziopharm Reports Second : Q2 loss per share $1.01 . Quarter 2016 financial results and provides update on recent activities . Q2 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S .Ziopharm oncology inc says recognized approximately $1.7 million in revenue during quarter in comparison with $0.3 million in revenue in 2015.  Full Article

Ziopharm Oncology updates on early study for brain cancer drug
Friday, 15 Jul 2016 09:25am EDT 

Ziopharm Oncology Inc : Ziopharm issues statement regarding phase 1 study of gene therapy candidate ad-RTS-hIL-12 in brain cancer . "first two patient deaths, which occurred 6.7 months and 3.9 months after treatment, were unrelated to study drug" . "for patients that remain in follow up in this phase i study, we believe that preliminary overall survival remains encouraging" . Third death has just been reported, collecting and analyzing information in order to properly and timely report it to fda . There have been no reported related instances of brain hemorrhage in pervious cohort or prior studies with ad-RTS-hIL-12 + veledimex . Cause of death for third patient is intracranial hemorrhage, which occurred some time after patient had been discharged from treating center .Enrollment remains open in study, will be discussing with safety review committee appropriate course of action.  Full Article

Intrexon and Ziopharm amend exclusive channel collaborations
Thursday, 30 Jun 2016 08:00am EDT 

Ziopharm Oncology Inc : Intrexon and Ziopharm amend exclusive channel collaborations to improve alignment as programs advance through development . New structure is intended to facilitate increased investment in clinical development by Ziopharm .Announced amendments to their exclusive channel collaborations (ECCS) in fields of oncology and graft-versus-host-disease.  Full Article

BRIEF-Ziopharm Oncology reports third quarter financial results

* Ziopharm Oncology reports third quarter 2017 financial results and provides update on recent activities